Based on the Alembic Pharmaceuticals Limited stock forecast from 2 analysts, the average analyst target price for Alembic Pharmaceuticals Limited is INR 865.75 over the next 12 months. Alembic Pharmaceuticals Limited’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Alembic Pharmaceuticals Limited is Slightly Bearish, which is based on 6 positive signals and 8 negative signals. At the last closing, Alembic Pharmaceuticals Limited’s stock price was INR 938.35. Alembic Pharmaceuticals Limited’s stock price has changed by -4.50% over the past week, +0.47% over the past month and +77.00% over the last year.
No recent analyst target price found for Alembic Pharmaceuticals Limited
No recent average analyst rating found for Alembic Pharmaceuticals Limited
Company Overview Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India. Address: Alembic Road, Vadodara, India, 390003 Read Less
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrol...Read More
Frequently Asked Questions About Alembic Pharmaceuticals Limited (APLLTD:NSE) Stock
Based on ratings from 2 analysts Alembic Pharmaceuticals Limited's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 4 hold ratings.
APLLTD:NSE stock's dividend yield is 0.86%.
Our analysis grades APLLTD:NSE stock's dividend yield at C+. This means that APLLTD:NSE stock's dividend yield is above 79% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this APLLTD:NSE may be a average dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for APLLTD:NSE is INR 865.75 over the next 12 months. The maximum analyst target price is INR 1023 while the minimum anlayst target price is INR 700.
APLLTD:NSE stock's Price/Earning ratio is 31.30.
Our analysis grades APLLTD:NSE stock's Price / Earning ratio at F. This means that APLLTD:NSE stock's Price/Earning ratio is above 43.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this APLLTD:NSE may be fairly valued for its sector
The last closing price of APLLTD:NSE's stock was INR 938.35.
The most recent market capitalization for APLLTD:NSE is INR 184.44B.
Based on targets from 2 analysts, the average taret price for APLLTD:NSE is projected at INR 865.75 over the next 12 months.
This means that APLLTD:NSE's stock price may go down by -7.74% over the next 12 months.
We can't find any ETFs which contains Alembic Pharmaceuticals Limited's stock.
As per our most recent records Alembic Pharmaceuticals Limited has 14,593 Employees.
Alembic Pharmaceuticals Limited's registered address is Alembic Road, Vadodara, India, 390003.
You can get more information about it from Alembic Pharmaceuticals Limited's website at https://alembicpharmaceuticals.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for APLLTD:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
